AzTrials
AzTrials

Respiratory FailureSHUMNCT01617798

Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis

A study testing Supplemental metolazone diuresis in people with Respiratory Failure and Volume Overload, run by Oregon Health and Science University at 1 site in United States.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

Patients who are on mechanical ventilation in an intensive care unit often require diursis as part of their pre-extubation regimen. The drug of choice for diuresis has traditionally been furosemide. However, this drug cause hypernatremia (a rise in serum sodium) in a significant proportion of patients. Read more about this study

Who is it for?
Any age
What is being tested?
Supplemental metolazone diuresis
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
0 participants
Where
1 siteUnited States
Study dates
Jun 2012to Jun 2013
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • ICU patients who are intubated and slated for diuresis in anticipation of extubation.
  • Patients must be hypernatremic (Na > 140 mEq/L) at the time diuresis is initiated or become hypernatremic over the course of receiving loop diuretics in anticipation of extubation.
  • GFR > 30 ml/min [as calculated by the MedCalc MDRD formula {GFR = 170 x PCr - 0.999 x Age - 0.176 x BUN - 0.170 x Albumin0.318 x 0.762 (for women) x 1.180 (for blacks)} ]

Who cannot join

  • History of allergy to furosemide or any thiazide diuretic
  • Inability to place enteral access
  • Moribund status

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Oregon Health Sciences University

    Portland, Oregon, 97239

Other trials in United States

About this study

Official title: Stop Hypernatremia, Use Metolazone for Aggressive, Controlled, Effective Diuresis

Patients who are on mechanical ventilation in an intensive care unit often require diursis as part of their pre-extubation regimen. The drug of choice for diuresis has traditionally been furosemide. However, this drug cause hypernatremia (a rise in serum sodium) in a significant proportion of patients. Hypernatremia is traditionally treated by providing free water supplementation to the patient. This strategy creates a vicious and unproductive cycle of giving free water, and then diuresing it off. We propose a strategy for breaking this cycle by using a second diuretic-- metolazone-- which has a tendency to rid the body of more sodium, thereby minimizing hypernatremia.

Read the detailed description

Mechanical ventilation is a mainstay of Intensive Care. Weaning from mechanical ventilation remains a significant issue in Intensive Care Unit (ICU) care worldwide. It is well established that a strategy of diuresis with negative fluid balance shortens the duration of mechanical ventilation in both acute lung injury and cardiogenic pulmonary edema patients. Despite publication of at least one formalized but complex evidence-based conservative fluid strategy, there is no practical, uniformly implemented protocol for setting or achieving volume status targets. The default approach at many hospitals involves using ad hoc doses (either intermittent or continuous) of a loop diuretic (usually furosemide) with instructions to monitor fluid balance and follow electrolytes in an attempt to reach arbitrary target volume diuresis. Moreover, there are barriers to achieving any particular target, including pre-existing renal failure/diuretic resistance, diuretic-induced creatinine elevation, acquired diuretic resistance, hypotension from volume loss, and electrolyte derangements including hypokalemia and hypernatremia. Strategies exist for preventing or treating the above complications but there is presently no accepted standard for preventing or treating diuretic-induced hypernatremia. In fact, the standard current intervention is to replace the free water deficit that may be induced by the loop diuretic, while simultaneously perpetuating the free water deficit by continuing to administer the causative loop diuretic. This approach is circular and does not effectuate the desired negative fluid balance. We will address the lack of an accepted prevention strategy using a randomized controlled clinical trial in ICU patients with the following specific aims:

  1. Conduct a randomized, pilot trial of standard versus metolazone supplemented diuresis in ICU patients with the primary outcome of improved negative fluid balance.
  2. Assess secondary outcomes including time to extubation, exacerbation of renal failure, and incidence of electrolyte derrangements in the treatment and control arms.
  3. Track whether initial hypernatremia within the control group is a risk factor for poor diuresis with furosemide, and whether it delays extubation.

The anticipated benefits of our proposed intervention involve fundamental ICU and patient care quality measures: avoiding the pitfalls of hypernatremia and diuretic resistance should lead to more effective diuresis, which should in turn lead to a more negative fluid balance, earlier liberation from the ventilator, and a shorter length of stay in the ICU.

Being tested
Supplemental metolazone diuresis, Placebo Comparator: Control-- furosemide (lasix) only
Medical subject headings
Respiratory Insufficiency, Edema, Hypernatremia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Supplemental metolazone diuresisDrug

    Also called furosemide, lasix

    Patients in the Study Arm will receive supplemental diuresis with metolazone 2.5 mg per dobhoff tube twice daily, in addition to furosemide as the primary team sees fit.

  • Placebo Comparator: Control-- furosemide (lasix) onlyDrug

    Also called furosemide, lasix, metolazone

    Control arm will receive furosemide as monotherapy for diuresis

Study groups in NCT01617798
Study groupRoleWhat they receive
Control-- furosemide (lasix) onlyPlacebo comparatorControl arm receives standard of care diuresis with furosemide(lasix)only. The treatment team will decide the dosing of furosemide (lasix). No actual placebo is administered.
Receives: Drug: Placebo Comparator: Control-- furosemide (lasix) only
Study ArmActive comparatorStudy arm receives evolving standard of care diuresis with furosemide and metolazone.
Receives: Drug: Supplemental metolazone diuresis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Fluid balance

    Differences in fluid balance (total net liters negative from the time diuresis is initiated) between the study group and control group at the following intervals: 24, 36, 48, and 72 hours after either protocol is initiated.

    Measured: 24, 36, 48, and 72 hours after either protocol is initiated

Secondary outcomes (4)
  1. Serum sodium

    Number patients whose Na remains below 145 (meq/L) during the period of diuresis; versus the number of patients whose sodium exceeds 145 (meq/L) and require free water replacement.

    Measured: Continuous for 72 hours

  2. Hyponatremia

    Number of patients who develop hyponatremia (Na < 136 meq/L)

    Measured: Continuous for up to 72 hours

  3. Time to extubation

    Time in hours from initiation of protocol to extubation (difference between study group and control group

    Measured: Unitl the patient is actually extubated, undergoes tracheostomy, or expires.

  4. Acute Kidney Injury

    Number of patients who develop acute kidney injury (increase in creatinine by more than 25%)

    Measured: Continuous for the first 72 hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jun 2012 (estimated)
  2. Study startJun 2012
  3. Primary completionJun 2013 (estimated)
  4. Study completionJun 2013 (estimated)

Why it stopped: Investigator departed organization

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01617798
Sponsor's protocol ID
IRB00007857
Acronym
SHUM
Status last verified
Jun 2019
First submitted
1 Jun 2012
Last updated
6 Jun 2019
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Supplemental metolazone diuresis in people with Respiratory Failure and Volume Overload, run by Oregon Health and Science University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 6 Jun 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Fluid balance (time frame: 24, 36, 48, and 72 hours after either protocol is initiated). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in